NMOSD

A global cohort study identified distinct clinical patterns and higher relapse rates in pediatric patients with MOGAD with non-P42 MOG antibody binding profiles.

Despite advancements in NMOSD treatments, the founder and executive director of the Sumaira Foundation discussed how misdiagnosis, delayed diagnosis, and disparities in care remain significant challenges. [WATCH TIME: 4 minutes]

The child neurologist and neuroimmunologist at Nationwide Children’s Hospital delved into the unique challenges and research objectives surrounding MOG antibody–associated disease. [WATCH TIME: 3 minutes]

Treatment strategies varied across cases, incorporating therapies like prednisolone, rituximab, and azathioprine, with overall positive outcomes and symptom improvement.

A post-hoc analysis of patients from the CHAMPION-NMOSD trial revealed that the majority received their initial meningococcal vaccination within 6-months of their last rituximab dose.

The child neurologist and neuroimmunologist at Nationwide Children’s Hospital provided clinical insight on the complexities of treating pediatric MOGAD, including treatment options, decision-making factors, and emerging therapies. [WATCH TIME: 4 minutes]

The assistant professor in the neurology department at the University of Utah in Salt Lake City discussed advancing personalized medicine for patients with neuromyelitis optica spectrum disorder, a rare disorder of the central nervous system. [WATCH TIME: 4 minutes]

A recent study reported that the presence of oligoclonal bands in cerebrospinal fluid of patients with myelin oligodendrocyte glycoprotein antibody-associated disease may be associated with a higher risk of relapse.

A newly developed advanced fMRI-based classification model demonstrated efficacy in distinguishing multiple sclerosis from neuromyelitis optica spectrum disorder, potentially having the ability to improve diagnostic accuracy.

Cerebrospinal fluid lipid profiling revealed potential biomarkers for distinguishing NMOSD from MS and tracking disease activity, offering new insights into neuroinflammatory disease monitoring.

A recent study reported significantly elevated cerebrospinal fluid inflammatory markers in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease during acute phases.

A 5-year retrospective analysis offered insights into disease characteristics, treatment responses, and clinical outcomes of neuromyelitis optica spectrum disorder as well as myelin oligodendrocyte glycoprotein antibody-associated disease.

A significant number of pregnancies in NMOSD patients experienced relapses postpartum, with 50% of pregnancies showing complications for both mother and fetus.

A large registry-based study analyzed treatment patterns and attack risks in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.

A unique case highlighted the complex interplay between NMOSD and other autoimmune diseases, demonstrating the challenges in diagnosing and managing the condition.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromyelitis optica spectrum disorder.

A 51-year-old patient with neuromyelitis optica spectrum disorder and hemorrhagic longitudinally extensive transverse myelitis presented a challenging case.

These findings underscore the potential of advanced imaging technologies to detect subtle gray matter differences, aiding in the accurate differentiation between MS and NMOSD.

A new study suggests particulate matter exposure exacerbated the severity of multiple sclerosis and neuromyelitis optica spectrum disorder, with significant clinical and radiological impacts.

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune CNS condition with distinct subtypes—AQP4-IgG positive, MOGAD, and double-negative—each requiring tailored diagnostic and treatment approaches.

Patients who started therapy immediately after the initial attack had a relapse risk of just 11% at 2 years and 20% at 6 and 8 years, compared to much higher rates (41% at 2 years, 56% at 8 years) in those who delayed therapy until a second attack.

Ultimately, the biomarkers' temporal patterns may help differentiate attacks from remission, with sGFAP being particularly useful in distinguishing genuine attacks from pseudoattacks.

A recent multicenter study showed that dried blood spot testing for neuromyelitis optica spectrum disorder provided high accuracy and practicality in resource-limited settings.

A new study revealed stark racial and socioeconomic disparities in pediatric neuromyelitis optica spectrum disorder outcomes, underscoring the need for targeted interventions.

In a longitudinal study lasting 2 years, impaired test performance in semantic fluency and congruent speed were observed in patients with MOGAD relative to healthy controls.